Dosage & Administration Drug label Prior authorization Financial assistance PubMed™ News

Mitigo

(morphine sulfate)

MITIGO 200 MG in 20 ML InjectionMITIGO 500 MG in 20 ML Injection

Dosage & administration

* Administration should be limited to use by those familiar with the management of respiratory depression. ( 2.1)
* Should be administered by or under the direction of a physician experienced in the techniques of epidural or intrathecal administration. ( 2.1)
* Patients should be observed in a fully equipped and staffed environment for at least 24 hours after each test dose and, as indicated, for the first several days after surgery. ( 2.1)
* Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. ( 2.2)
* Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse. ( 2.2)
* Initial Dosage: Must be individualized, based upon in-hospital evaluation of the response to serial single-dose epidural bolus injections of regular morphine sulfate injection, USP 0.5 mg/mL or 1 mg/mL, with close observation for analgesic efficacy and adverse effects prior to surgery involving the continuous microinfusion device. ( 2.2)
* Dosage for Epidural Administration: Initial dose range of 3.5 to 7.5 mg/day for patients with no tolerance to opioids. The usual starting dose for continuous epidural infusion in patients with some degree of opioid tolerance is 4.5 to 10 mg/day and may increase significantly during treatment to 20-30 mg/day. ( 2.3)
* Dosage for Intrathecal Administration: Initial dose range of 0.2 to 1 mg/day for patients with no tolerance to opioids. The range of doses for patients with some degree of opioid tolerance varies from 1 to 10 mg/day. Doses above 20 mg/day should be employed with caution. ( 2.4)
* Do not stop MITIGO abruptly in a physically dependent patient. ( 2.6)